Corticosteroids were the mainstay of therapy for idiopathic pulmonary fibrosis (IPF) for more than four decades, but their efficacy is unproven and toxicities are substantial. The course of IPF is characterized by progressive respiratory insufficiency, leading to death within 3 to 8 years from the onset of symptoms. Although a subset (10-20%) of patients survives more than 10 years, there is no evidence that any form of therapy alters the natural history of the disease. Nonetheless, given the poor prognosis, a trial of corticosteroids is often given. Because of the rarity of IPF, randomized, placebo-controlled therapeutic trials have not been done. Further, no studies have compared differing dosages or duration of corticosteroid in matched patients. Interpretation of therapy efficacy is obscured by several factors including heterogeneous patient populations, inclusion of patients with histologic entities other than usual interstitial pneumonia, lack of objective, validated endpoints, different criteria for "response." We review published data regarding corticosteroid therapy for IPF and present a rationale for stratifying therapy based on host, demographic, and clinical factors that influence prognosis as well as risk for corticosteroid complications.
Corticosteroids (CS) have been the mainstay of therapy for idiopathic pulmonary fibrosis (IPF) for more than four decades [1-3], but their efficacy is unproven [4••,5-7] and toxicities are substantial [4••,8••]. The terms IPF and cryptogenic fibrosing alveolitis (CFA) are synonymous [3, 9, 10] . A recent international consensus statement concluded "usual interstitial pneumonia (UIP) is the histopathologic pattern that identifies patients with IPF" [3] . Other histologic patterns have a better prognosis and higher rate of response to CS than UIP and are considered distinct entities [3] . Cardinal features of IPF/CFA include dry cough, exertional dyspnea, endinspiratory Velcro rales, diffuse parenchymal infiltrates on chest radiographs, honeycomb cysts, a restrictive defect on pulmonary function tests (PFT), impaired gas exchange, and impaired oxygenation (Table 1) [3,10-12]. The course is indolent but inexorable with progressive respiratory failure [13] . Fewer than 40% survive 5 years; the mean survival is 2.8 to 3.6 years [4••,5,7,14-17]. Because IPF/CFA is rare (estimated prevalence rates of three to 20 cases per 100,000 population) [3, 12, 18, 19] , randomized, placebo-controlled therapeutic trials have not been done. CS are most often used, but dose, rate of taper, and duration differ among studies [1,2,10,20-22]. Interpretation of published data is misleading because patients with histologic entities other than UIP (and that have a better prognosis than UIP) were included in earlier reports of IPF/CFA.
Definition of idiopathic pulmonary fibrosis
Historically, the histologic lesion UIP was considered to represent a subset of patients with IPF [23, 24] . Current recommendations restrict the term IPF to patients with idiopathic UIP [3] . Other types of idiopathic interstitial pneumonia (IIP) include desquamative interstitial pneumonia (DIP) [24, 25] , respiratory bronchiolitis interstitial lung disease (RBILD) [25] , nonspecific interstitial pneumonia/fibrosis (NSIP) [14, 15, 17, 26, 27] , acute interstitial pneumonia [28, 29] , lymphoid interstitial pneumonia [30] , and cryptogenic organizing pneumonia, also termed bronchiolitis obliterans organizing pneumonia [31] . These types of IIP have a better prognosis and higher rates of response to CS compared with UIP. A definitive diagnosis of UIP requires surgical (open or video-assisted thoracoscopic lung biopsy) [3, 25] , but the diagnosis of UIP can be confirmed with confidence by thin-section high-resolution computed tomography (HRCT) scans in some patients [27, 32] . Most published series of IPF or CFA likely incorporated a mixture of histologic entities [1, 2, [20] [21] [22] [23] 33, 34] ; it is plausible that most steroid-responsive cases of IPF represented disor-ders other than UIP. When the diagnosis of UIP is substantiated, response to therapy is poor and mortality is high [14, 15, 17, 27] .
Histopathologic features of usual interstitial pneumonia
The cardinal histopathologic features of UIP include bilateral but heterogeneous (patchy) involvement, a predilection for the lower lobes and peripheral (subpleural) regions, fibroblastic foci (aggregates of proliferating fibroblasts and myofibroblasts), excessive collagen and extracellular matrix (ECM), and honeycomb cysts [3, 25] . Mononuclear cell infiltrates (eg, lymphocytes, plasma cells, macrophages) and scattered neutrophils and eosinophils may be present within alveolar septa, but inflammatory changes are not conspicuous [25] . The heterogeneity of the histologic lesion can be seen at low-power magnification; areas of normal lung interstitial inflammation, fibrosis, and honeycomb cysts are observed concomitantly [3, 25] . Additional features of UIP include traction bronchiectasis and bronchiolectasis, reduced airspace volume, destroyed or distorted alveolar architecture, smooth muscle hypertrophy, reactive metaplasia and hyperplasia of type II pneumocytes, mucostasis, and secondary pulmonary hypertensive changes [17, 25] . 
Which histologic features differentiate usual interstitial pneumonia from other idiopathic interstitial pneumonias?

High-resolution computed tomography
High-resolution CT scans, using 1-to 2-mm thin sections, are often used in lieu of surgical lung biopsies to diagnose UIP [3, 14, 27, 40, 41] . Provided HRCT features are classical, the accuracy of a confident diagnosis of UIP on HRCT by a trained observer is greater than 90% [3,42,43]. However, a confident diagnosis of UIP can be made in less than two thirds of patients with histologic UIP [3, 43] . Inter-and intraobserver variability can be problematic for inexperienced radiologists, particularly in less severe cases [44] .
What are the salient high-resolution computed tomography features that allow a confident diagnosis of usual interstitial pneumonia?
Characteristic HRCT features of UIP include a distinct predilection for the basilar and peripheral (subpleural) regions of the lungs, patchy involvement, large areas of spared lung parenchyma, coarse reticular or linear opacities (intralobular and interlobular septal lines), honeycomb cysts, and traction bronchiectasis or bronchiolectasis [15, 27, 39, 45, 46] HRCT was a better predictor of survival than pulmonary function tests (PFT), clinical/radiographic/physiologic scores, or pathologic scores (from surgical lung biopsies).
Pathogenesis of usual interstitial pneumonia
The pathogenesis of UIP is unclear, but epithelial cell injury, destruction of subepithelial basement membrane, recruitment and proliferation of fibroblasts, and excessive deposition of extracellular matrix (ECM) and collagen are pivotal in orchestrating the fibrotic process [65] are the primary sites of ongoing injury and repair, leading to collagen deposition [62] . Transforming growth factor ␤1 stimulates fibroblast proliferation and differentiation into myofibroblasts, stimulates synthesis of collagen and ECM proteins, inhibits synthesis of proteases that degrade the ECM, and likely plays a pivotal role in orchestrating fibrogenesis in UIP [62, 66] . Fibroblasts and myofibroblasts from patients with UIP induce apoptosis and necrosis of alveolar epithelial cells in vitro [62, 67] . Alveolar epithelial shedding, in turn, releases transforming growth factor ␤1 from ECM, which promotes myofibroblast production of collagen [68] . Fibroblasts from patients with UIP demonstrate enhanced production of collagens [58••], increased expression of tissue inhibitors of metalloproteinases, and a relative decrease in collagenases [62, 69] ; all these processes promote the formation of scar.
Alveolar macrophages elaborate profibrotic cytokines (eg, platelet-derived growth factor [70] , insulin-like growth factor I [71] , interleukin-1 [72] ), ECM proteins [70] , and free oxygen radicals [73] , which may be important in the pathogenesis of UIP.
Production, deposition, and proteolysis of ECM are critical to pulmonary remodeling, repair, and development of fibrosis. ECM proteins (eg, tenascin [65, 74] , fibronectin [58••], collagen [75] ) are expressed in increased amounts in UIP. In the initial phases, both type III and I collagen accumulate; later, type I predominates [75] . Type I collagen reflects irreversible fibrosis attributable to greater resistance to metalloproteinase digestion [62]. Tenascin, another ECM protein, is present in increased amounts in UIP [65] and may correlate inversely with survival [74] . Another ECM protein, fibronectin may be important in the pathogenesis of UIP. Fibronectin acts as a growth factor and chemoattractant for fibroblasts [62, 76] . In one study, alveolar macrophages from patients with UIP produced fibronectin at a rate 20 times higher than normal alveolar macrophages [77] ; this may promote local recruitment of fibroblasts and collagen deposition, promoting local fibrosis.
Angiogenesis and the production of angiogenic factors by host cells likely contribute to the pathogenesis of UIP. Neovascularization may promote fibrogenesis [62], perhaps by supplying blood to rapidly proliferating fibroblasts within fibroblastic foci. Chemokines (chemotactic cytokines) may promote fibrosis in patients with IPF [78] . Other angiogenic molecules, such as vascular endothelial growth factor and acidic and basic fibroblast growth factor may be involved in the pathogenesis of UIP, but data are lacking [78] .
Other molecules believed to play some role in the pathogenesis of UIP include interleukin-1 receptor antagonist [79] , integrin-mediated adhesion molecules [80] , surfactant proteins [81] , and oxidants [82] . In summary, alveolitis and chronic inflammation likely play roles in the pathogenesis of UIP, but their importance is probably minor [62] . The most critical factors orchestrating the fibrotic process are altered fibroblast phenotype and interactions between immune and nonimmune cells, which lead to profibrotic cytokines. Elucidating the mechanisms of fibrosis in UIP will facilitate the development of novel, targeted therapies for this devastating disease. [87] have been used to treat IPF/CFA but are of unproven benefit. In 1995, Hunninghake and Kalica [88] , summarizing a working conference on IPF convened by the National Heart, Lung, and Blood Institute (NHLBI) in 1994 noted that "there was a general consensus at the workshop that pulmonary fibrosis is a highly lethal lung disorder and that current therapies for this disease have little effect on the natural history of the disease." In 1999, a summary of a 1998 NIHLBI workshop on IPF arrived at a similar conclusion: "…these observations suggest that current therapy has minimal or no beneficial effect for patients with IPF" [89] . More recently, a recent International Consensus Statement concluded "no data exist that adequately document any of the current treatment approaches improves survival or the quality of life for patients with IPF" [3]. These conclusions are sobering and suggest that novel therapies are essential to improve the prognosis of this fatal disorder [88, 89] . In this review, we focus on the role (if any) of CS to treat IPF/CFA. A discussion of other potential therapies for IPF/CFA is beyond the scope of this paper and is addressed only briefly.
Therapy of idiopathic pulmonary fibrosis
Impact of corticosteroids in idiopathic pulmonary fibrosis: results of retrospective studies
The What is the response to corticosteroids among idiopathic pulmonary fibrosis patients in prospective randomized trials?
A few randomized therapeutic trials compared CS with immunosuppressive or cytotoxic agents [20, 21, 23, 90] or colchicine [40] as therapy for IPF. These studies did not subclassify patients as UIP. One 6-month study at the National Institutes of Health randomized 28 patients with mid-course IPF to prednisone alone (n = 16), prednisone plus oral CP (n = 9), or CP alone (n = 5) [90] . At 6 months, PFT or chest radiographs did not change in any group. Another prospective trial in England randomized 43 patients with untreated IPF to high-dose prednisolone alone (60 mg/d with gradual taper) or oral CP plus low-dose prednisolone (20 mg every other day) [21] . Symptoms, chest radiographs, and PFT were monitored as endpoints. Seven of 22 patients (31%) receiving prednisolone alone showed initial improvement. At 3 years, only two patients treated with prednisolone alone maintained improvement, and 15 had worsened (10 deaths). Two prospective studies evaluated high-dose prednisolone plus AZA for IPF [20, 23] . In the first study, 20 patients with progressive IPF were treated with highdose prednisone alone for 3 months [23] . At 3 months, AZA, 3 mg/kg/d, was added, and both agents were continued for an additional 9 months or longer. Overall, 12 patients (60%) improved (defined as increase in vital capacity Ն 20% above baseline) but the concomitant use of AZA obscures the effect of prednisone. In a second, double-blind trial by these investigators, 27 patients with newly diagnosed IPF were randomized to receive AZA plus high-dose prednisone, 1.5 mg/kg/d, with taper (n = 14) or high-dose prednisone plus placebo (n = 13) [20].
At 1 year, four patients died in each group. Changes in PFT were minimal and were similar between groups. At 1 year, vital capacity improved (>10% above baseline) in three of 13 patients receiving prednisone alone; DLCO improved (> 20% above baseline) in only two patients. At long-term follow-up (at a mean of 9 years), 77% in the prednisone plus placebo cohort had died (compared with 43% of AZA-treated patients). This survival difference was not statistically significant (P = 0.16). Investigators at the Mayo Clinic randomized 26 patients with idiopathic UIP to colchicine (0.6 mg once or twice daily) (n = 14) or high-dose prednisone (n = 12) [40]. PFT did not improve in any subject in either group. Side effects were more frequent and severe in the prednisone cohort. A prospec-tive but nonrandomized study from Mexico evaluated four patient cohorts with IPF [87] . Treatment regimens included colchicine plus prednisone (n = 19); Dpenicillamine plus prednisone (n = 11); prednisone plus colchicine plus D-penicillamine (n = 11) or prednisone alone (n = 15). Five-year mortality was 52% and did not differ between treatment groups [87] . 
Complications of corticosteroid therapy
Corticosteroid therapy is associated with myriad adverse effects that are related to both the dose and duration of treatment [95, 96] . Table 2 . Although CS benefits some patients, the high incidence of adverse effects underscores the need to stratify risk for CS complications when treatment is being contemplated. In the following sections, we discuss ways to minimize the risk of CS adverse effects.
Osteoporosis
Osteoporosis is a well-recognized complication of CS and can lead to fractures [98] . Potential mechanisms by which CS lead to bone loss and osteoporosis include decreased production of testosterone, decreased calcium absorption, increased calcium excretion, and decreased production of osteocalcin by osteoblasts [99] . Simple nonpharmacologic measures advocated to reduce bone loss include (1) increasing activity, (2) maintaining good nutrition, (3) refraining from smoking, and (4) modulating consumption of alcohol [99] . Supplemental calcium and vitamin D are recommended for patients receiving CS, but this strategy does not consistently prevent osteoporosis in high-risk patients. The risk of fractures is increased considerably among patients receiving highdose CS. In a recent study, the risk of hip fracture over 4 years was doubled in patients taking oral CS compared with that of controls [100] . In another study of 367 patients taking CS for diverse lung diseases, the cumulative incidence of fractures (all sites) was 23% for patients receiving oral CS compared with 15% in controls not receiving CS (OR: 1.8) [95] . More important, among CStreated patients, the risk of fractures was markedly increased (compared with controls) at the following sites: vertebrae (OR: 10), hips (OR: 6), and ribs or sternum (OR: 3.2).
Measurement of bone mineral density (BMD) is recommended as a proxy measure of bone strength and to assess the risk of fracture [98] . Baseline BMD should be measured in patients receiving long-term CS treatment, particular in the elderly or postmenopausal women [98] . Pharmacologic therapy should be considered for patients with BMD 1 to 2 SD below normal or for patients with a history of fracture [99] . Calcium and vitamin D have been used for many years for the treatment of osteoporosis. A recent meta-analysis demonstrated a clinically and statistically significant prevention of bone loss from the lumbar spine and forearm with calcium and vitamin D in CS-treated patients [101] . Those authors recommended prophylactic therapy with calcium and vitamin D for all patients who are being started on CS [101] . This recommendation is most appropriate for patients with low dietary calcium intake (< 1.0-1.5 g/d) and without contraindications to supplemental calcium (eg, renal calculi) [99] . Patients with a history of fracture or baseline osteoporosis should be given bisphosphonates (eg, alendronate, risedronate) [102] because these agents are beneficial in treating and preventing CS-induced osteoporosis [99, [103] [104] [105] . A recent meta-analysis including 13 trials and 842 patients taking at least 7.5 mg/d prednisone confirmed that bisphosphonates improve BMD [101] . The risk of spinal fractures was reduced 24%, although this was not statistically significant (OR: 0.76; 95% CI: 0.37, 1.53) [101] . Data regarding other potential therapies (eg, androgens, fluoride, intranasal calcitonin) are limited.
The role of these agents in the treatment or prevention of CS-associated osteoporosis needs to be elucidated.
Peptic ulcer disease
The association of CS use and peptic ulcer disease (PUD) is controversial. CS were associated with an increased risk of PUD and gastrointestinal hemorrhage in some studies [106] , but a meta-analysis failed to find an increased incidence of PUD among CS-treated patients compared with controls [107] . Given the conflicting data, the risk (if any) of PUD associated with CS appears to be small. In our series, only one of 41 patients (2.5%) treated with high-dose prednisone for 3 months developed a peptic ulcer [8••]. Because endoscopies were only performed for clinical indications, occult (asymptomatic) disease could have been missed. The benefit of histamine-2 antagonists or antacids to prevent PUD in CStreated patients has not been established. However, patients with a history of PUD or receiving concomitant medications that increase the risk of PUD (eg, nonsteroidal antiinflammatory agents) may benefit from prophylaxis with histamine-2 antagonists or proton pump inhibitors. The use of prophylaxis in other low-risk populations needs to be individualized.
Miscellaneous complications of corticosteroids
As outlined in Table 2 , CS have protean side effects, ranging from life-threatening opportunistic infections to cosmetic changes (eg, Cushingoid features). For some patient populations (eg, age > 70, significant obesity, diabetes mellitus, serious psychiatric disease), the risk of CS often exceeds the benefit. In such patients, we consider alternative therapeutic modalities. Among CS-treated patients, careful monitoring and patient education are essential to identify complications to modify dose or therapy at the earliest possible time.
Recent consensus statements and recommendations for therapy
Given the potential for debilitating side effects with CS therapy, recent editorials [108, 109] 
Novel (future) agents
Unfortunately, current therapies for IPF based on altering the inflammatory component are marginally effective. The dictum nollo nocere is highly relevant, when potentially toxic drugs such as CS or immunosuppressive or cytotoxic agents are used for prolonged periods of time. Judicious and careful use of these drugs, with objective monitoring, is mandatory. Major advances in the treatment of IPF/UIP await the development of novel therapies that prevent fibroproliferation and/or enhance alveolar reepithelialization [58••]. Agents that have been tested in pilot studies include pirfenidone (5-methyl-1phenyl-2-[1H]-pyridone) [114] , N-acetylcysteine [115] , and interferon-␥ [97] . Novel agents that inhibit fibrosis in vitro or in animal models and are worthy of study in future clinical trials include captopril [58••,116], platelet-activating factor receptor antagonists, inhibitors of leukocyte integrins, cytokines or proteases [88, 117] , keratinocyte growth factor [118, 119] , relaxin [120] , and lovastatin [121] . Comprehensive review of 487 patients with IPF/UIP seen at the Mayo Clinic Rochester from 1994 to 1996. By univariate analysis, worse survival was associated with prednisone therapy compared with no therapy and with oxygen therapy compared with no oxygen therapy. On multivariate analysis, worse survival was associated with older age, male gender, lower DLCO, lower alveolar volume, and a history of worsening pulmonary function. When adjustments were made for these factors, no significant difference in survival was found between untreated patients and treated patients (all modalities).
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